Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes

Jonathan CohenPharmacy Services, Oregon Health & Science University, Portland, OR, USA; Correspondence[email protected]

Alison PalumboPharmacy Services, Oregon Health & Science University, Portland, OR, USA;

Jason WingPharmacy Services, Oregon Health & Science University, Portland, OR, USA;

Michael C. HeinrichPortland VA Health Care System and OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA

http://orcid.org/0000-0003-3790-0478

Click to increase image sizeClick to decrease image size

Disclosure statement

AP is consultant at Dedham Group and Oncology Reimbursement Management. MCH is consultant at Novartis, Molecular MD and holds equity interest in Molecular MD.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes

Information for

Open access

Opportunities

Help and information

Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature